GlobeNewswire: uniQure Contains the last 10 releaseshttp://globenewswire.com/External?Length=42016-12-10T05:06:06ZGlobeNewswirehttp://globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)http://globenewswire.com/news-release/2016/09/26/874583/10165312/en/uniQure-to-Present-at-the-Jefferies-Gene-Editing-and-Gene-Therapy-Summit-in-New-York-City.html?f=22&fvtc=4&fvtv=20166uniQure to Present at the Jefferies Gene Editing and Gene Therapy Summit in New York City2016-09-26T13:18:35Z<![CDATA[LEXINGTON, Mass. and AMSTERDAM, The Netherlands, Sept. 26, 2016 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leader in human gene therapy, today announced that Matt Kapusta, interim chief executive officer, will present an overview of the company's programs and progress at the Jefferies Gene Editing/Gene Therapy Summit on Tuesday October 11th at the Jefferies Conference Center in New York City:]]>http://globenewswire.com/news-release/2016/09/22/874009/10165282/en/uniQure-Announces-Management-and-Board-Changes.html?f=22&fvtc=4&fvtv=20166uniQure Announces Management and Board Changes2016-09-22T20:18:09Z<![CDATA[LEXINGTON, Mass. and AMSTERDAM, The Netherlands, Sept. 22, 2016 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leader in human gene therapy, today announced that its Board of Directors has accepted the resignation of Daniel Soland as chief executive officer (CEO) and an executive member of the Board, effective immediately. The Board is pleased to announce that Matthew Kapusta, the Company's chief financial officer (CFO) since January 2015 who also serves as an executive member of the Board, has been appointed interim CEO. In addition, Philip Astley-Sparke, a member of the Board of Directors and former President of uniQure's US operations, has been elected unanimously by the Board to serve as its Chairman. ]]>http://globenewswire.com/news-release/2016/09/16/872431/10165146/en/uniQure-Receives-NASDAQ-Deficiency-Letter-Related-to-Board-Composition.html?f=22&fvtc=4&fvtv=20166uniQure Receives NASDAQ Deficiency Letter Related to Board Composition2016-09-16T11:13:40Z<![CDATA[LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Sept. 16, 2016 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leader in human gene therapy, today announced that it has received a letter from NASDAQ dated September 12, 2016, stating that the Company does not currently comply with the requirement under NASDAQ Listing Rule 5605 that at least a majority of the Company's Board consist of independent directors. Currently, four of the eight members of the Company's Board meet NASDAQ's independence standards; this is a result of the retirements from the Board of independent directors Ferdinand Verdonck and Joseph Fezko effective as of the Company's 2016 annual general meeting of shareholders. Under the NASDAQ rules, the Company has until the earlier of its next annual shareholders' meeting or June 15, 2017 to regain compliance with the majority independent board requirement (or until December 12, 2016, if the Company holds its next annual general meeting of shareholders prior to such date). The Company intends to achieve compliance with this requirement prior to the expiration of this cure period.]]>http://globenewswire.com/news-release/2016/08/25/867121/10164816/en/uniQure-Announces-Financial-Results-For-Second-Quarter-2016-and-Update-on-Company-Progress.html?f=22&fvtc=4&fvtv=20166uniQure Announces Financial Results For Second Quarter 2016 and Update on Company Progress2016-08-25T20:18:17Z<![CDATA[~ Progress Across the Pipeline~ Additional data on AMT-060 in Hemophilia B Expected Later this Year~Data from Sanfilippo B and Parkinson's Disease Studies Expected in Q1 2017~Strong Balance Sheet to Support Advancement of Programs]]>http://globenewswire.com/news-release/2016/08/25/867109/0/en/uniQure-Announces-Financial-Results-For-Second-Quarter-2016-and-Update-on-Company-Progress.html?f=22&fvtc=4&fvtv=20166uniQure Announces Financial Results For Second Quarter 2016 and Update on Company Progress2016-08-25T20:05:00Z<![CDATA[~ Progress Across the Pipeline~ Additional data on AMT-060 in Hemophilia B Expected Later this Year~Data from Sanfilippo B and Parkinson’s Disease Studies Expected in Q1 2017~Strong Balance Sheet to Support Advancement of Programs]]>http://globenewswire.com/news-release/2016/08/17/864814/10164600/en/uniQure-to-Present-at-Upcoming-Investor-Conferences-in-September.html?f=22&fvtc=4&fvtv=20166uniQure to Present at Upcoming Investor Conferences in September2016-08-17T11:12:17Z<![CDATA[LEXINGTON, Mass. and AMSTERDAM, The Netherlands, Aug. 17, 2016 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leader in human gene therapy, today announced that members of its leadership team will present an overview of the company's programs and progress at several upcoming investor conferences. These meetings include the following:]]>http://globenewswire.com/news-release/2016/07/27/859389/10164292/en/uniQure-Presents-Updated-Clinical-Data-in-Patients-with-Severe-Hemophilia-B-Demonstrating-up-to-9-Months-of-Sustained-Levels-of-Factor-IX-Activity-and-Therapeutic-Effect.html?f=22&fvtc=4&fvtv=20166uniQure Presents Updated Clinical Data in Patients with Severe Hemophilia B Demonstrating up to 9 Months of Sustained Levels of Factor IX Activity and Therapeutic Effect2016-07-27T18:27:21Z<![CDATA[
--Data from Low-Dose Cohort of AMT-060 Clinical Trial Continues to Show Durability and Therapeutically Relevant Factor IX (FIX) Activity in Severe, Older Patients with Advanced Joint Disease and Frequent Bleeding Episodes--]]>http://globenewswire.com/news-release/2016/07/11/855106/10164034/en/uniQure-Announces-Oral-Presentation-of-Updated-Results-for-AMT-060-at-the-World-Federation-of-Hemophilia-WFH-2016-World-Congress.html?f=22&fvtc=4&fvtv=20166uniQure Announces Oral Presentation of Updated Results for AMT-060 at the World Federation of Hemophilia (WFH) 2016 World Congress2016-07-11T17:54:25Z<![CDATA[AMSTERDAM, The Netherlands, July 11, 2016 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leader in human gene therapy, today announced that updated data from its ongoing Phase I/II clinical study of AMT-060 in hemophilia B patients will be presented at the World Federation of Hemophilia 2016 World Congress being held July 24-28, 2016 in Orlando, Florida. ]]>http://globenewswire.com/news-release/2016/07/07/854260/10163960/en/uniQure-Appoints-Jonathan-Garen-as-Chief-Business-Officer.html?f=22&fvtc=4&fvtv=20166uniQure Appoints Jonathan Garen as Chief Business Officer2016-07-07T10:43:38Z<![CDATA[AMSTERDAM, the Netherlands, July 7, 2016 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leader in human gene therapy, today announced the appointment of Jonathan Garen as Chief Business Officer. Mr. Garen has more than 20 years of experience in business development within the pharmaceutical sector, having previously held senior positions at Actavis plc, Forest Laboratories, Inc. and Pharmacia Corporation. Mr. Garen will be responsible for strategic transactions at uniQure, with a focus on business development and alliance management. Mr. Garen will report to Daniel Soland, Chief Executive Officer of uniQure, and will be based in the Company's Lexington, Massachusetts facility. ]]>http://globenewswire.com/news-release/2016/06/27/851467/10163726/en/uniQure-Appoints-Maria-E-Cantor-as-Senior-Vice-President-Investor-Relations-Communications.html?f=22&fvtc=4&fvtv=20166uniQure Appoints Maria E. Cantor as Senior Vice President, Investor Relations & Communications2016-06-27T10:30:00Z<![CDATA[
AMSTERDAM, the Netherlands, June 27, 2016 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leader in human gene therapy, today announced the appointment of Maria E. Cantor as Senior Vice President, Investor Relations and Communications. Ms. Cantor joins the Company from ARIAD Pharmaceuticals, Inc. where she most recently held the role of Senior Vice President, Corporate Affairs. With over 20 years of experience in communications in the biotech and healthcare industry, she will lead external communications for uniQure, including investor relations, media and digital communications, and corporate image and branding. She will serve as a member of the Company's senior management team and will be based in its Lexington, Massachusetts facility.]]>